

ChineseCVD: first-in-world, web-based, Chinese-specific Cardiovascular Risk Calculator incorporating long COVID, COVID-19 vaccination, SGLT2i and PCSK9i treatment effects

Carlin Chang¹, Gary Tse^{2,3}, Quincy Lee⁴, Oscar Hou In Chou^{1,4,5}, Teddy Tai Loy Lee⁶, Bosco Kwok-hei Leung⁶, Amy Lee Ngai¹, Adan Khan⁷, Wing Tak Wong⁸, Abraham Ka Chung Wai⁶, Kang-yin Chen, Tong Liu #³, Jiandong Zhou #¹⁰

¹ Division of Neurology, Department of Medicine, Queen Mary Hospital, Hospital Authority, Hong Kong, China

² School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China

³ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

⁴ Family Medicine Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China

⁵ Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

⁶ Department of Emergency Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

⁷ Kent and Medway Medical School, University of Kent, Canterbury, United Kingdom

⁸ School of Life Science, The Chinese University of Hong Kong, Hong Kong, China

⁹ Division of Health Science, Warwick Medical School, University of Warwick, Coventry, United Kingdom

Correspondence to:

Tong Liu MD PhD FESC FACC

Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University

Tianjin 300211, China

School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China

Email: liutongdoc@126.com

Jiandong Zhou PhD

Division of Health Science, Warwick Medical School, University of Warwick, Coventry, United Kingdom

Email: jiandong.zhou@warwick.ac.uk

Abstract

Background: Web-based risk prediction tools for cardiovascular diseases are crucial for providing rapid risk estimates for busy clinicians, but there is none available specifically for Chinese subjects. This study developed ChineseCVD, first-in-world web-based Chinese-specific Cardiovascular Risk Calculator incorporating long COVID, COVID-19 vaccination, SGLT2i and PCSK9i treatment effects.

Methods: Adult patients attending government-funded family medicine clinics in Hong Kong between 1st January 2000 and 31st December 2003 were included. The primary outcome was major adverse cardiovascular events (MACE) defined as a composite of myocardial infarction, heart failure, transient ischaemic attacks/ischaemic strokes, and cardiovascular mortality.

Results: A total of 155,066 patients were used as the derivation cohort. Over a median follow-up of 16.1 (11.6-17.8) years, 31,061 (20.44%) had MACE. Cox regression identified male gender, age, comorbidities, cardiovascular medications, systolic and diastolic blood pressure, and laboratory test results (neutrophil-lymphocyte ratio, creatinine, ALP, AST, ALT, HbA1c, fasting glucose, triglyceride, LDL and HDL) as significant predictors of the above outcomes. ChineseCVD further incorporates the impact of smoking status, COVID-19 infection, number of COVID-19 vaccination doses, and modifier effects of newest medication classes of PCSK9i and SGLT2i. The calculator enables clinicians to demonstrate to patients how risks vary with different medications.

Conclusions: The ChineseCVD risk calculator enables rapid web-based risk assessment for adverse cardiovascular outcomes, thereby facilitating clinical decision-making at the bedside or in the clinic.

Key words: Chinese; cardiovascular disease; risk calculator

Introduction

Cardiovascular diseases (CVDs), including myocardial infarction, heart failure, transient ischaemic attacks/ischaemic strokes, are leading causes of mortality, morbidity, and lower quality of life globally. Risk prediction tools or calculators are crucial for providing rapid risk estimates for busy clinicians, guiding decision making and clinical management at both primary and secondary care levels. The most popular CVD calculators include ASCVD Risk Estimator + created by the American College of Cardiology, Framingham Risk Score and QRisk3, but others also exist, including Reynolds Risk Score ¹, Pan American Health Organization Cardiovascular Risk Calculator ², AusCVDRisk ³, New Zealand cardiovascular risk prediction equations ⁴.

However, as noted in an Editorial by our team published in 2018 ⁵, there is no tool that is tailored and individualised specifically for Chinese subjects. Since 2020, we have been conducting population-based studies evaluating risk factors for CVDs, with a focus on blood pressure ^{6,7}, lipid ⁸ and glycemic tests ⁹, as well as measures of their visit-to-visit variability, for risk prediction for myocardial infarction, stroke, heart failure, dementia ¹⁰ and other outcomes such as anxiety ¹¹ and bone fractures ¹². The ultimate goal has been the creation and development of risk models that are enhanced by AI. Our unique approach is personalised care, with individualised risk prediction based on different diseases. The first-in-world Chinese-specific CVD risk models were published by other teams ¹³⁻¹⁶. To further enhance risk prediction using state-of-the-art AI technology, our team recently reported on the development of PowerAI-CVD, which is the first Chinese-specific, validated artificial intelligence-powered *in-silico* predictive model for CVD ¹⁷. The model was developed from large historical cohort of Hong Kong Chinese patients attending publicly managed family medicine clinics between 2000 and 2003 with two decades of follow-up data available for myocardial infarction, heart failure and transient ischaemic attacks/ischaemic strokes separately, as well as their composite outcome (major adverse cardiovascular events), at 1-, 3-, 5-, 10- and 20- year time points.

Whilst the enhancement by AI can significantly improve the predictive performance and it can be embedded in health record systems in the form of a dashboard, the complexity of the algorithm represents a barrier for implementation in routine clinical settings. By contrast, a web-based calculator has the capability of being easily accessible and can be used by busy clinicians by the bedside or in the clinic. In 2020, our team was amongst the first to develop a Chinese-specific risk calculator for prediction of severe COVID-19 disease, which was made freely available on QxMD ¹⁸. In this study, we present a Chinese-specific risk calculator based on these published findings. The major novelty of our model is the incorporation of factors include prior COVID-19 infection, COVID-19 vaccination and consideration of treatment effects including the latest drug class such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Methods

Ethics approval and study cohort

This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board (HKU/HA HKWC IRB) (UW-20-250 and UW 23-339) and The Joint Chinese University of Hong Kong (CUHK) Hospital Authority New Territories East Cluster (NTEC) Clinical Research Ethics Committee (CREC) (2018.309 and 2018.643). It also complied with the Declaration of Helsinki.

This was a retrospective population-based study of prospectively collected electronic health records using the Clinical Data Analysis and Reporting System (CDARS) managed by the Hong Kong Hospital Authority (HA). These records include information from public hospitals, their affiliated outpatient clinics, day-care centres and ambulatory care facilities. This system has been used extensively by research groups from Hong Kong¹⁸⁻²⁰.

The procedures for data extraction and data analysis has been described in the previous study¹⁷. Briefly, the inclusion criteria were patients attending family clinics managed by the Hospital Authority of Hong Kong between 1st January 2000 and 31st December 2003. The exclusion criteria were patients who died within 30 days of the baseline date or who were <18 years old. The following clinical information was extracted during the baseline period, defined as 1st January 2000 to 31st December 2003: demographic details (age and gender), blood pressure (mean systolic blood pressure [SBP] and diastolic blood pressure [DBP]), existing diseases of diabetes mellitus, hypertension, chronic obstructive pulmonary disease, ischaemic heart disease, heart failure, myocardial infarction, and stroke/TIA, prescription details of different cardiovascular drugs. The diseases were defined using International Classification of Diseases (ICD)-9 codes (**Supplementary Appendix: Table 1**). Complete blood count, liver and renal function tests, glycemic and lipid tests during the baseline period were extracted.

Outcomes and statistical analysis

The primary outcome was MACE, defined as any of the following events: myocardial infarction, heart failure, TIA/stroke and cardiovascular mortality, with follow-up until 31st December 2019. Continuous variables were presented as median (95% confidence interval [CI] or interquartile range [IQR]) and categorical variables are shown as frequency (%). The Mann-Whitney U test was used to compare continuous variables. The χ^2 test with Yates' correction was used for 2x2 contingency data, and Pearson's χ^2 test was used for contingency data for variables with more than two categories. All statistical tests were two-tailed

and considered significant with $P < 0.05$. Analyses were conducted using RStudio software (Version: 1.1.456) or Python (Version: 3.6).

Development of predictive models and validation

To develop the ChineseCVD model, we followed the approach taken by the pooled cohort equation model, where we used a historical cohort for derivation followed by a contemporary cohort for validation²¹. Cox regression was used to identify significant predictors of MACE. The natural logarithm values of the hazard ratios were used for model development, with 3-, 5-, 10- and 20-year risks estimated using cohort-level event rates at these time points. For validation of 5-year CVD risk, an independent cohort of patients attending family medicine clinics managed by the Hong Kong West Cluster (HKWC) of the Hospital Authority in 2019, excluding patients in the 2000 to 2003 cohort used for model development, will be used. The model will then be recalibrated and tested using another independent cohort of patients attending family medicine clinics managed by clusters other than HKWC.

Results

Model development and validation

In the development cohort, a total of 155066 patients were included. Of these, 31,061 (20.44%) patients had MACE over a median follow-up of 16.1 (11.6-17.8) years. Cox regression identified age, male gender, SBP, DBP, diabetes mellitus, hypertension, hypertension treatment with antihypertensive, COPD, IHD, IHD treatment with antiplatelet, MI, HF, AF, AF treatment with anticoagulant, TIA/stroke, NLR, creatinine, ALP, ALT, triglyceride, LDL, HDL, HbA1c and fasting glucose as significant predictors. The risks of smoking status were obtained from the analysis of the China Kadoorie Biobank²². To incorporate the novel variables of prior COVID-19 infection²³, number of COVID-19 vaccination doses²⁴ and initiation of statins²⁵, SGLT2i²⁶ or PCSK9i²⁷ therapy, HRs were identified from these published studies and added to our model, termed ChineseCVD. The corresponding beta values are shown in **Table 1** and a graphical interface of ChineseCVD is shown in **Figure 1**. Validation for 5-year CVD risk using an independent cohort of patients attending family medicine clinics managed by the Hong Kong West Cluster of the Hospital Authority in 2019 will be performed. The model will then be recalibrated and tested using another independent cohort of patients attending family medicine clinics managed by clusters other than HKWC.

Discussion

The main findings of this study are the development of ChineseCVD, a web-based risk prediction tools freely available to clinicians and investigators worldwide for predicting incident cardiovascular events. The novelty is that our model incorporates new variables of previous COVID-19 infection, the number of COVID-19 vaccination doses, and treatment effects of cardiovascular medications, such as statins and PCSK9i, and the newest antidiabetic medication class, SGLT2i.

A number of risk calculators are currently available for cardiovascular risk prediction, including QRISK3®²⁸, developed from the QResearch database that contains data from General practices in England, and ACC/AHA Pooled Cohort Cardiovascular Risk Equations, developed from primary data of studies published in the pre-statin era, including the Atherosclerosis Risk In Communities study²⁹, Cardiovascular Health Study³⁰, Coronary Artery Risk Development in Young Adults study³¹, which were combined with data from the Framingham³² and Framingham Offspring³³ studies. By contrast, there are few risk scores developed specifically for Asian populations and yet Asians different from Western individuals in terms of genetics, culture, lifestyle, social and behavioural characteristics³⁴. Relevant for cardiovascular risk, the Asia Pacific Cohort Studies Collaboration found higher systolic blood pressure, total cholesterol, and cardiovascular event rates in the Framingham cohort compared to six cohort studies from Japan, Korea and Singapore, and six cohort studies from China³⁵. Given these differences, direct application of Western risk models will inevitably lead to inaccuracies in the risk estimates³⁶. Therefore, our team recently developed the first Chinese-specific, validated artificial intelligence-powered *in-silico* predictive model for cardiovascular disease, called PowerAI-CVD¹⁷. Comparing different artificial intelligence approaches, we found that CatBoost significantly outperformed XGBoost, Gradient Boosting, Multilayer Perceptron, Random Forest, Naive Bayes, Decision Tree, k-Nearest Neighbor, AdaBoost, SVM-Sigmoid and logistic regression, showing a classification accuracy of . Strikingly, it showed significant prediction performance across different subgroups of age, sex and both for primary and secondary prevention purposes.

To facilitate implementation, this study proposes a simplified, score-based risk calculator, ChineseCVD, based on these validated risks. The novelty of ChineseCVD is the consideration of treatment effects, specifically statins and new drug classes of PCSK9i and SGLT2i. Our model also incorporated the impact of long COVID on the cardiovascular system, as well as the protective effects of COVID-19 vaccination on MACE. These features deal with the limitations of existing risk calculators, where the scores do not consider initiation of antiplatelet drugs, statins and antihypertensive medications. Current risk models have the limitation of overestimating CVD risk, which is partly attributed to the lack of statin use in historical cohort years from which the models were developed.

ChineseCVD is specifically designed for the primary care settings, as the model development had utilised family medicine clinic data. Our unique approach is personalised care, with individualised risk

prediction based on different diseases and outcomes. Thus, we have developed CVD risk models for diabetes mellitus³⁷⁻³⁹, which captured data from both primary and secondary care settings. The first version, PowerAI-Diabetes, third-in-world, Chinese-specific AI-driven predictive model for predicting diabetic complications and first-in-world to incorporate lipid and glycaemic variability with AI, was recently developed⁴⁰. We are incorporating new information such as treatment effects of first- and second-line anti-diabetic medications, such as metformin, sulphonylureas^{41,42}, SGLT2 inhibitors, DPP4 inhibitors, GLP1 agonists^{43,44}, which would impact on the risks of CVD and other adverse events. Our AI-enhanced diabetes model complement previously published, Chinese-specific diabetes CVD risk models by other groups^{45,46}. Our future model will also capture fluctuations in inflammation using biomarkers⁴⁷. Finally, we are developing cancer-specific CVD risk models based on our recent publications⁴⁸, most notably our series on prostate cancer⁴⁹⁻⁵³.

Conclusions

The ChineseCVD risk calculator enables rapid web-based risk assessment for adverse cardiovascular outcomes, thereby facilitating clinical decision-making at the bedside or in the clinic.

References

1. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. Feb 14 2007;297(6):611-9. doi:10.1001/jama.297.6.611
2. Ordunez P, Tajer C. Disseminating cardiovascular disease risk assessment with a PAHO mobile app: a public eHealth intervention. *Rev Panam Salud Publica*. Jul 2015;38(1):82-5.
3. Nelson M. Absolute cardiovascular disease risk and the use of the Australian cardiovascular disease risk calculator. *Aust J Gen Pract*. Aug 2020;49(8):471-473. doi:10.31128/AJGP-12-19-5174
4. Holt A, Batinica B, Liang J, et al. Development and validation of cardiovascular risk prediction equations in 76 000 people with known cardiovascular disease. *European Journal of Preventive Cardiology*. 2023;zwad314. doi:10.1093/eurjpc/zwad314
5. Tse G, Roeber L, Wong MCS, Liu T. Cardiovascular risk assessment tools in non-Western populations. *Int J Cardiol*. Dec 1 2018;272:331-332. doi:10.1016/j.ijcard.2018.08.030
6. Zhou J, Lee S, Wong WT, et al. Associations between Five-Year Blood Pressure Variability and Risk of Cardiovascular Events and Mortality. *medRxiv*. 2020:2020.12.21.20248682. doi:10.1101/2020.12.21.20248682
7. Zhou J, Lee S, Wong WT, et al. Gender-specific clinical risk scores incorporating blood pressure variability for predicting incident dementia. *J Am Med Inform Assoc*. Jan 12 2022;29(2):335-347. doi:10.1093/jamia/ocab173
8. Chan JSK, Satti DI, Lee YHA, et al. High visit-to-visit cholesterol variability predicts heart failure and adverse cardiovascular events: a population-based cohort study. *Eur J Prev Cardiol*. Oct 20 2022;29(14):e323-e325. doi:10.1093/eurjpc/zwac097
9. Wang Y, Zhou J, Qi W, et al. Visit-to-Visit Variability in Fasting Blood Glucose Predicts the New-Onset Heart Failure: Results From Two Large Chinese Cohorts. *Current Problems in Cardiology*. 2023/09/01/2023;48(9):101842. doi:<https://doi.org/10.1016/j.cpcardiol.2023.101842>

10. Lee S, Zhou J, Liu T, Zhang Q, Tse G. Gender-specific clinical risk scores incorporating blood pressure variability for predicting incident dementia. *J Am Med Inform Assoc*. Sep 12 2022;29(10):1825-1826. doi:10.1093/jamia/ocac117
11. Zhou J, Lee S, Wong WT, et al. Gender- and Age-Specific Associations of Visit-to-Visit Blood Pressure Variability With Anxiety. *Front Cardiovasc Med*. 2021;8:650852. doi:10.3389/fcvm.2021.650852
12. Zhou J, Li H, Chang C, et al. The association between blood pressure variability and hip or vertebral fracture risk: A population-based study. *Bone*. Sep 2021;150:116015. doi:10.1016/j.bone.2021.116015
13. Liu X, Shen P, Zhang D, et al. Evaluation of Atherosclerotic Cardiovascular Risk Prediction Models in China: Results From the CHERRY Study. *JACC: Asia*. 2022/02/01/ 2022;2(1):33-43. doi:<https://doi.org/10.1016/j.jacasi.2021.10.007>
14. Li HH, Huang S, Liu XZ, Zou DJ. Applying the China-PAR Risk Algorithm to Assess 10-year Atherosclerotic Cardiovascular Disease Risk in Populations Receiving Routine Physical Examinations in Eastern China. *Biomed Environ Sci*. Feb 2019;32(2):87-95. doi:10.3967/bes2019.014
15. Yang X, Li J, Hu D, et al. Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China). *Circulation*. Nov 8 2016;134(19):1430-1440. doi:10.1161/CIRCULATIONAHA.116.022367
16. Zhang Y, Miao H, Chia YC, et al. Cardiovascular risk assessment tools in Asia. *J Clin Hypertens (Greenwich)*. Apr 2022;24(4):369-377. doi:10.1111/jch.14336
17. Li L, Chou OHI, Lu L, et al. PowerAI-CVD - the first Chinese-specific, validated artificial intelligence-powered in-silico predictive model for cardiovascular disease. *medRxiv*. 2023:2023.10.08.23296722. doi:10.1101/2023.10.08.23296722
18. Zhou J, Lee S, Wang X, et al. Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. *NPJ Digit Med*. Apr 8 2021;4(1):66. doi:10.1038/s41746-021-00433-4
19. Lee S, Zhou J, Li KHC, et al. Territory-wide cohort study of Brugada syndrome in Hong Kong: predictors of long-term outcomes using random survival forests and non-negative matrix factorisation. *Open Heart*. Feb 2021;8(1)doi:10.1136/openhrt-2020-001505
20. Liu Y, Ling L, Wong SH, et al. Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. *EClinicalMedicine*. Jul 2021;37:100955. doi:10.1016/j.eclinm.2021.100955
21. Ridker PM, Cook NR. The Pooled Cohort Equations 3 Years On. *Circulation*. 2016/12/06 2016;134(23):1789-1791. doi:10.1161/CIRCULATIONAHA.116.024246
22. Shen Q, Zhu NB, Yu CQ, et al. [Sex-specific associations between tobacco smoking and risk of cardiovascular diseases in Chinese adults]. *Zhonghua Liu Xing Bing Xue Za Zhi*. Jan 10 2018;39(1):8-15. doi:10.3760/cma.j.issn.0254-6450.2018.01.002
23. Lam ICH, Wong CKH, Zhang R, et al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. *EClinicalMedicine*. Jun 2023;60:102000. doi:10.1016/j.eclinm.2023.102000
24. Wan EYF, Mok AHY, Yan VKC, et al. Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study. *Cell Rep Med*. Sep 13 2023:101195. doi:10.1016/j.xcrm.2023.101195
25. Blais JE, Ye X, Wan EYF, et al. Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients. *Clin Drug Investig*. Nov 2022;42(11):987-997. doi:10.1007/s40261-022-01208-9
26. Barbarawi M, Al-abdouh A, Barbarawi O, Lakshman H, Al kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. *Heart Failure Reviews*. 2022/05/01 2022;27(3):951-960. doi:10.1007/s10741-021-10083-z
27. Chou OHI, Li L, Chung CTS, et al. Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based Study. *medRxiv*. 2023:2023.09.23.23296003. doi:10.1101/2023.09.23.23296003

28. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*. 2017;357:j2099. doi:10.1136/bmj.j2099
29. Investigators AS. The decline of ischaemic heart disease mortality in the ARIC study communities. *International Journal of Epidemiology*. 1989;18(Supplement_1):S88-S98.
30. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. *Ann Epidemiol*. Feb 1991;1(3):263-76. doi:10.1016/1047-2797(91)90005-w
31. Kapur A, Malik I, Bagger J, et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: Background, aims, and design. *American heart journal*. 2005;149(1):13-19.
32. Dawber TR, Meadors GF, Moore Jr FE. Epidemiological approaches to heart disease: the Framingham Study. *American Journal of Public Health and the Nations Health*. 1951;41(3):279-286.
33. Wilson PW, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring Study. *JAMA*. 1989;262(1):41-44.
34. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation*. Dec 4 2001;104(23):2855-64. doi:10.1161/hc4701.099488
35. Asia Pacific Cohort Studies C, Barzi F, Patel A, et al. Cardiovascular risk prediction tools for populations in Asia. *J Epidemiol Community Health*. Feb 2007;61(2):115-21. doi:10.1136/jech.2005.044842
36. Lee CH, Woo YC, Lam JK, et al. Validation of the Pooled Cohort equations in a long-term cohort study of Hong Kong Chinese. *J Clin Lipidol*. Sep-Oct 2015;9(5):640-6 e2. doi:10.1016/j.jacl.2015.06.005
37. Lee S, Zhou J, Wong WT, et al. Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. *BMC Endocr Disord*. May 4 2021;21(1):94. doi:10.1186/s12902-021-00751-4
38. Lee S, Zhou J, Leung KSK, et al. Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong. *BMJ Open Diabetes Res Care*. Jun 2021;9(1)doi:10.1136/bmjdr-2020-001950
39. Lee S, Zhou J, Guo CL, et al. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. *Endocrinol Diabetes Metab*. Jul 2021;4(3):e00240. doi:10.1002/edm2.240
40. Tse G, Lee Q, Chou OHI, et al. Healthcare Big Data in Hong Kong: development and implementation of artificial intelligence-enhanced predictive models for risk stratification. *Curr Probl Cardiol*. Oct 21 2023;102168. doi:10.1016/j.cpcardiol.2023.102168
41. Lee TTL, Hui JMH, Lee YHA, et al. Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study. *J Am Heart Assoc*. Sep 20 2022;11(18):e026289. doi:10.1161/JAHA.122.026289
42. Zhou J, Zhang G, Chang C, et al. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study. *Acta Diabetol*. May 2022;59(5):697-709. doi:10.1007/s00592-021-01841-4
43. Lee S, Zhou J, Leung KSK, et al. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong. *Cardiovasc Drugs Ther*. Jun 2023;37(3):561-569. doi:10.1007/s10557-022-07319-x
44. Zhou J, Liu X, Chou OH, et al. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. *Rheumatology (Oxford)*. Apr 3 2023;62(4):1501-1510. doi:10.1093/rheumatology/keac509
45. Liang J, Li Q, Fu Z, et al. Validation and comparison of cardiovascular risk prediction equations in Chinese patients with Type 2 diabetes. *European Journal of Preventive Cardiology*. 2023;30(12):1293-1303. doi:10.1093/eurjpc/zwad198
46. Liang J, Pylypchuk R, Tang X, et al. Rationale, design and population description of the CREDENCE study: cardiovascular risk equations for diabetes patients from New Zealand and Chinese electronic health

records. *European Journal of Epidemiology*. 2021/10/01 2021;36(10):1085-1095. doi:10.1007/s10654-021-00795-9

47. Chang C, Zhou J, Chou OHI, et al. Predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: The Hong Kong Diabetes Study. *Endocrinol Diabetes Metab*. Jan 2023;6(1):e397. doi:10.1002/edm2.397

48. Chung CT, Lakhani I, Chou OHI, et al. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study. *Cancer Med*. Jun 2023;12(11):12299-12315. doi:10.1002/cam4.5927

49. Chan JSK, Lee YHA, Hui JMH, et al. Long-term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population-based competing risk analysis. *Int J Cancer*. Aug 15 2023;153(4):756-764. doi:10.1002/ijc.34557

50. Chan JSK, Satti DI, Lee YHA, et al. Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study. *Br J Cancer*. Jun 2023;128(12):2253-2260. doi:10.1038/s41416-023-02271-5

51. Chan JSK, Lee YHA, Hui JMH, et al. Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study. *Clin Oncol (R Coll Radiol)*. Jun 2023;35(6):e376-e383. doi:10.1016/j.clon.2023.03.014

52. Chan JSK, Lee YHA, Liu K, et al. HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy. *Eur Urol Open Sci*. Jan 2023;47:3-11. doi:10.1016/j.euros.2022.11.002

53. Chan JSK, Lee YHA, Liu K, et al. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy. *Eur J Clin Invest*. Apr 2023;53(4):e13932. doi:10.1111/eci.13932

Table 1. Univariable Cox regression to predict MACE in patients attending family medicine clinics.

Characteristics	MACE	
	HR [95% CI];P value	Beta coefficient
<i>Demographics</i>		
Male gender	1.13 [1.11-1.16]	0.122217633
Baseline age, year	1.04 [1.04-1.05]	0.039220713
BP (Systolic)-mean	1.029 [1.029-1.030]	0.028587457
BP (Diastolic)-mean	0.979 [0.978-0.981]	-0.021223636
Current smoker (male)	1.28 [1.23-1.34]	0.246860078
Ex-smoker (male)	1.06 [0.99-1.14]	0.058268908
Current smoker (female)	1.17 [1.10-1.26]	0.157003749
Ex-smoker (female)	1.09 [0.93-1.26]	0.086177696
<i>Comorbidities</i>		
Diabetes mellitus	2.75 [1.99-3.80]	1.011600912
Hypertension	3.47 [3.35-3.60]	1.244154594
Chronic obstructive pulmonary disease	4.67 [4.12-5.30]	1.541159072
Ischemic heart disease	4.04 [3.81-4.29]	1.396244692
Heart failure	15.44 [14.42-16.54]	2.736961545
Myocardial infarction	4.39 [3.70-5.21]	1.479329227
Atrial fibrillation	9.25 [8.56-10.00]	2.224623552
Transient ischaemic attack/Stroke	4.64 [4.23-5.09]	1.534714366
Antihypertensive treatment	0.66 [0.63-0.68]	-0.419979151
Antiplatelet treatment	0.82 [0.78-0.87]	-0.193272388
Anticoagulant treatment	0.25 [0.22-0.25]	2.224623552
SGLT2i treatment	0.86 [0.80-0.93]	-0.15082289
PCSK9i treatment	0.59 [0.37-0.92]	-0.527632742
Any COVID-19 disease	1.12 [1.05-1.19]	0.113328685
Severe COVID-19 disease	1.99 [1.04-3.76]	0.6886325
COVID-19 vaccination (1 dose)	0.79 [0.71-0.88]	-0.235722334
COVID-19 vaccination (2 doses)	0.63 [0.58-0.69]	-0.46203546

COVID-19 vaccination (3 doses)	0.59 [0.54-0.66]	-0.527632742
Laboratory tests		
Neutrophil-to-lymphocyte ratio	1.022 [1.020-1.025]	0.021761492
Creatinine, umol/L	1.003 [1.003-1.003]	0.002995509
Alkaline phosphatase, U/L	1.001 [1.001-1.001]	0.0009995
Alanine transaminase, U/L	0.999 [0.998-0.999]	-0.0010005
Mean triglyceride, mmol/L	0.97 [0.95-0.98]	1.8494
Mean low-density lipoprotein, mmol/L	0.69 [0.67-0.70]	2.5412
Mean high-density lipoprotein, mmol/L	0.53 [0.51-0.55]	1.1338
Mean HbA1C, %	1.08 [1.06-1.10]	7.9857
Mean fasting glucose, mmol/L	1.08 [1.07-1.08]	5.6113

Figure 1. ChineseCVD Web calculator for instantons calculation of 5-year MACE risk.

Age: 77 **Gender:** F **BP:** 147/60 mmHg

Past Medical History:

Diabetes mellitus

Hypertension

COPD

IHD

Heart failure

MI

AF

TIA/stroke

COVID infection

No. of COVID vaccine doses:

Smoking

Never

Ex

Current

Existing Medications:

Antihypertensive

Antiplatelet

Anticoagulant

Statin

Ezetimibe

PCSK9i

SGLT2i

13%

5-year CVD Risk: HIGH

[Click for risks of specific events:](#)

MI

Stroke

HF

CV Death

Laboratory tests

NLR	2.37	HbA1c	6.3
Creatinine	57	Fasting glucose	6.5
ALP	50	Triglyceride	1.8
AST	25	LDL	2.9
ALT	43	HDL	1.2

Age: 77 Gender: F BP: 147/60 mmHg



ChineseCVD



13%

Past Medical History:

- Diabetes mellitus
- Hypertension
- COPD
- IHD
- Heart failure
- MI
- AF
- TIA/stroke
- COVID infection
- No. of COVID vaccine doses:

Smoking

- Never
- Ex
- Current

Existing Medications:

- Antihypertensive
- Antiplatelet
- Anticoagulant
- Statin
- Ezetimibe
- PCSK9i
- SGLT2i

5-year CVD Risk:

HIGH

[Click for risks of specific events:](#)



MI



Stroke



HF



CV Death

Laboratory tests

NLR	2.37	HbA1c	6.3
Creatinine	57	Fasting glucose	6.5
ALP	50	Triglyceride	1.8
AST	25	LDL	2.9
ALT	43	HDL	1.2